AZN long ideaGreen lines are targets, will go down a bit but then I think it will go back up
not financial advice
Key facts today
Next report date
≈
July 24
Report period
Q2 2025
EPS estimate
1.10 USD
Revenue estimate
14.04 B USD
2.51 USD
7.04 B USD
54.07 B USD
3.10 B
About ASTRAZENECA PLC ORD USD0.25
Sector
Industry
CEO
Pascal Soriot
Website
Headquarters
Cambridge
Founded
1992
FIGI
BBG000BZ0DK8
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
10%
13%
16%
19%
22%
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
0.00
4.00 B
8.00 B
12.00 B
16.00 B
Revenue
Net income
Net margin %
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
0.00
3.50 B
7.00 B
10.50 B
14.00 B
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
0.00
3.50 B
7.00 B
10.50 B
14.00 B
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
0.00
9.00 B
18.00 B
27.00 B
36.00 B
Debt
Free cash flow
Cash & equivalents
No news here
Looks like there's nothing to report right now
Supply and Demand Trading Made Simple With Astrazeneca StockIn the ever-evolving world of stock trading, where news headlines can shift markets in a heartbeat, savvy investors often turn to the age-old principles of supply and demand to find clarity. Enter AstraZeneca stock (NASDAQ: AZN) — a biopharmaceutical titan that has played a pivotal role in global he
Astrazeneca potentially to $88AstraZeneca’s share price has been hovering around a long-term trend line established since 2017. Historically, each time the price has tested this trend line, it has rebounded sharply, suggesting strong investor confidence.
From 2017 to 2023, the company’s financial performance has been notably ro
BULLISH ON AZNAstraZeneca's Q3 2024 earnings exceeded expectations, with a revenue increase of 18%, signaling healthy demand for its products, especially in oncology and rare diseases.
Technicals - Key Indicators:
RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not ye
Astrazeneca (Wait for correction to complete)Hello,
To demonstrate how we can leverage TradingView for informed investment decisions, let’s analyze AstraZeneca as our example today. I will follow a structured approach and provide an investment recommendation based on both fundamental and technical insights.
Understanding the Business
Befor
AZN eyes on $71: Double Fib support that could launch a leg up AZN daily chart shows a significant pullback.
Currently testing a double Fib (Genesis+Covid).
Long entry option with a tight SL just below fibs.
$ 70.95-71.01 is the tight support of interest.
$ 80.48-81.11 would be an optimistic target.
===========================================
.
AstraZeneca - GBP | Chart & Forecast SummaryKey Indicators on Trade Set Up in General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Active Sessions on Relevant Range & Elemented Probabilities;
* Asian(Ranging) - London(Upwards) - NYC(Downwards)
* Weekend Crypto Session
Trend | Time Frame Conductive | Weekly Time Frame
- General Tr
AZN Astrazeneca plc ADRI’ve been closely monitoring AZN, which has been trading on the upside for a while now. Given the recent momentum, it appears to be approaching a point where a downward move could be imminent. I believe the stock might be ready to take a dip, presenting a potential opportunity for a downside play.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US46353AX6
ASTRAZENECA 20/50Yield to maturity
7.58%
Maturity date
Aug 6, 2050
US46353AZ1
ASTRAZENECA 21/51Yield to maturity
6.90%
Maturity date
May 28, 2051
US46353AU2
ASTRAZENECA 18/48Yield to maturity
6.11%
Maturity date
Aug 17, 2048
US46353AM0
ASTRAZENECA PLC 15/45Yield to maturity
6.07%
Maturity date
Nov 16, 2045
AZN3901525
AstraZeneca PLC 4.0% 18-SEP-2042Yield to maturity
6.05%
Maturity date
Sep 18, 2042
AZN.GE
AstraZeneca PLC 6.45% 15-SEP-2037Yield to maturity
5.15%
Maturity date
Sep 15, 2037
US46353AW8
ASTRAZENECA 20/30Yield to maturity
4.87%
Maturity date
Aug 6, 2030
US46353AL2
ASTRAZENECA PLC 15/25Yield to maturity
4.77%
Maturity date
Nov 16, 2025
See all AZN bonds
Curated watchlists where AZN is featured.
